IGFBP2 and cancer: The exposition of cancer cells to methylation inhibitor (5-Aza-2′-Deoxycytidine (AZA)), produced re-expression of IGFBP2, and increased in abundance of IGFBP2, indicating that IGFBP2 could be epigenetically silenced [106].